1
|
Navarro-Triviño FJ, Cassini-Gómez de Cádiz VA. Allergic contact dermatitis caused by Intrasite Conformable and Cutimed Sorbact wound dressings. Contact Dermatitis 2022; 86:562-564. [PMID: 35229309 DOI: 10.1111/cod.14087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 02/23/2022] [Accepted: 02/24/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Francisco J Navarro-Triviño
- Department of Contact Eczema and Immunoallergic Diseases, Dermatology, Hospital Universitario San Cecilio, Granada
| | - Víctor Alfredo Cassini-Gómez de Cádiz
- Hospital Universitario San Cecilio, Granada. Specialized nurse of Contact Eczema and Immunoallergic Diseases, Dermatology, Hospital Universitario San Cecilio, Granada
| |
Collapse
|
2
|
Impact of trends in new and emerging contact allergens. Int J Womens Dermatol 2022; 8:e006. [PMID: 35620033 PMCID: PMC9112390 DOI: 10.1097/jw9.0000000000000006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Accepted: 12/09/2021] [Indexed: 11/26/2022] Open
Abstract
Allergic contact dermatitis represents a T cell-mediated, delayed-type hypersensitivity response to exogenous agents. While allergic contact dermatitis is one of the most common causes of skin disease encountered by dermatologists, emerging trends within the field are in constant flux, as influenced by ever-changing industry practices and evolving consumer behaviors. Although certain allergens continue to predominate, new chemicals are frequently being introduced, thus shifting the pattern of allergen exposure and sensitization. This review examines the impact of trends in new and emerging contact allergens, with particular attention to clinical contexts in which these agents may be encountered. In addition, we offer a working knowledge of these allergens’ characteristics, sources, and relevance, while outlining recommendations to accurately evaluate, diagnose, and provide appropriate counseling for these diseases.
Collapse
|
3
|
Teufel-Schäfer U, Huhn C, Müller S, Müller C, Grünert SC. Severe allergic contact dermatitis to two different continuous glucose monitoring devices in a patient with glycogen storage disease type 9b. Pediatr Dermatol 2021; 38:1302-1304. [PMID: 34418148 DOI: 10.1111/pde.14767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Continuous glucose monitoring (CGM) systems are of great value for patients with disorders of impaired glucose homeostasis, including glycogen storage diseases. We report on an 8-year-old girl with glycogen storage disease type 9b who developed severe allergic contact dermatitis to two different continuous glucose monitoring systems, FreeStyle® Libre and Dexcom® G6. Our case highlights the impact of sensitization for pediatric patients, the urgent need for open labeling of components by pharmaceutical and device manufacturers, and the need for avoidance of skin sensitizers in medical devices.
Collapse
Affiliation(s)
- Ulrike Teufel-Schäfer
- Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center- University of Freiburg, Faculty of Medicine, Freiburg, Germany
| | - Christian Huhn
- Department of Dermatology, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany
| | - Sabine Müller
- Department of Dermatology, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany
| | - Christoph Müller
- Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center- University of Freiburg, Faculty of Medicine, Freiburg, Germany
| | - Sarah Catharina Grünert
- Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center- University of Freiburg, Faculty of Medicine, Freiburg, Germany
| |
Collapse
|
4
|
Navarro-Triviño FJ, Vega-Castillo JJ, Llamas-Molina JM, Ruiz-Villaverde R. Refractory Head and Neck atopic dermatitis pattern treated with Dupilumab: Allergic contact dermatitis caused by decyl glucoside. Should surfactants be patched? Australas J Dermatol 2021; 62:509-511. [PMID: 34374433 DOI: 10.1111/ajd.13678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2021] [Revised: 07/01/2021] [Accepted: 07/21/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Francisco J Navarro-Triviño
- Department of Contact Eczema and Immunoallergic Diseases, Dermatology, Hospital Universitario San Cecilio, Granada, Spain
| | | | | | | |
Collapse
|
5
|
Herman A, Uter W, Rustemeyer T, Matura M, Aalto-Korte K, Duus Johansen J, Gonçalo M, White IR, Balato A, Giménez Arnau AM, Brockow K, Mortz CG, Mahler V, Goossens A. Position statement: The need for EU legislation to require disclosure and labelling of the composition of medical devices. J Eur Acad Dermatol Venereol 2021; 35:1444-1448. [PMID: 33955077 PMCID: PMC8251888 DOI: 10.1111/jdv.17238] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Accepted: 03/08/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND In recent years, skin reactions secondary to the use of medical devices (MD), such as allergic contact dermatitis have increasingly been observed (e.g. to continuous blood sugar monitoring systems, insulin pumps, wound dressings, medical gloves, etc.): this is regarded as a developing epidemic. Lack of labelling of the composition of MD, as well as frequent lack of cooperation of manufacturers to disclose this relevant information, even when contacted by the clinician for the individual case of an established adverse reaction, significantly impede patient care. OBJECTIVES To advocate for full ingredient labelling in the implementation of EU regulation for MD. METHODS This position paper reviews the scientific literature, the current regulatory framework adopted for MD to date, and the likely impact, including some costs data in case of the absence of such labelling. RESULTS Efforts made by several scientific teams, who are trying to identify the culprit of such adverse effects, either via asking for cooperation from companies, or using costly chemical analyses of MD, can only partly, and with considerable delay, compensate for the absence of meaningful information on the composition of MD; hence, patient management is compromised. Indeed, without knowing the chemical substances present, physicians are unable to inform patients about which substances they should avoid, and which alternative MD may be suitable/tolerated. CONCLUSION There is an urgent need for full and accurate labelling of the chemical composition of MD in contact with the human body.
Collapse
Affiliation(s)
- A Herman
- Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium
| | - W Uter
- Department of Medical Informatics, Biometry and Epidemiology, Univ. Erlangen/Nürnberg, Erlangen, Germany
| | - T Rustemeyer
- Department of Dermatology and Allergology, Amsterdam University Medical Centres, Amsterdam, The Netherlands
| | - M Matura
- Dermatology Unit, Skaraborgs Hospital Skövde, Skövde, Sweden
| | - K Aalto-Korte
- Occupational Health Unit, Finnish Institute of Occupational Heath, Helsinki, Finland
| | - J Duus Johansen
- Department of Dermatology and Allergy, National Allergy Research Centre, Herlev-Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
| | - M Gonçalo
- Department of Dermatology, Coimbra University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - I R White
- Cutaneous Allergy Team, St. John's Institute of Dermatology, Guy's Hospital, London, UK
| | - A Balato
- Department of Advanced Biomedical Sciences, University of Naples Federico II, Napoli, Italy
| | - A M Giménez Arnau
- Department of Dermatology, Hospital del Mar. Universitat Autònoma de Barcelona, Barcelona, Spain
| | - K Brockow
- Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany
| | - C G Mortz
- Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark
| | - V Mahler
- Med. Faculty, Univ. Erlangen/Nuremberg, Erlangen, Germany
| | - A Goossens
- Contact Allergy Unit, Department of Dermatology, University Hospital KU Leuven, Leuven, Belgium
| | | |
Collapse
|
6
|
Contact Allergy to Topical Drugs. Contact Dermatitis 2021. [DOI: 10.1007/978-3-030-36335-2_38] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
7
|
Ulriksdotter J, Svedman C, Bruze M, Glimsjö J, Källberg K, Sukakul T, Mowitz M. Contact dermatitis caused by glucose sensors-15 adult patients tested with a medical device patch test series. Contact Dermatitis 2020; 83:301-309. [PMID: 32608015 DOI: 10.1111/cod.13649] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 06/23/2020] [Accepted: 06/28/2020] [Indexed: 12/15/2022]
Abstract
BACKGROUND Several cases of allergic contact dermatitis (ACD) to the glucose sensor FreeStyle Libre have been reported. Isobornyl acrylate (IBOA) and N,N-dimethylacrylamide (DMAA) are known culprit allergens. OBJECTIVES To evaluate patients with suspected ACD to FreeStyle Libre in a standardized manner, present causative allergens, and assess patient-reported implications. METHODS A total of 15 patients with suspected ACD to FreeStyle Libre were patch tested with the Swedish baseline series and a new medical device series. IBOA and DMAA were tested at 0.1% and 0.3% in petrolatum (pet.). Readings were performed on day (D) 3 and D7. Background data, details on skin reactions, and associated implications were assessed using a questionnaire. RESULTS Thirteen patients were sensitized to IBOA and four to DMAA. Two positive reactions to IBOA and one to DMAA were seen only at 0.3% concentration on D7. Median duration of sensor use before dermatitis onset was 6 months. Half the number of the patients took precautions in everyday life due to sensor-related skin reactions. Six patients discontinued sensor usage. CONCLUSIONS Patients with suspected ACD to glucose sensors should be evaluated with a relevant patch test series containing IBOA and DMAA. Adding the 0.3% pet. concentration is recommended. The reading on D7 is necessary.
Collapse
Affiliation(s)
- Josefin Ulriksdotter
- Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.,Department of Dermatology, Helsingborg Hospital, Helsingborg, Sweden
| | - Cecilia Svedman
- Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Magnus Bruze
- Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Jenny Glimsjö
- Department of Medicine, Blekinge Hospital, Karlskrona, Sweden
| | - Kajsa Källberg
- Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden
| | - Thanisorn Sukakul
- Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.,Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Martin Mowitz
- Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden
| |
Collapse
|
8
|
Contact Allergy-Emerging Allergens and Public Health Impact. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2020; 17:ijerph17072404. [PMID: 32244763 PMCID: PMC7177224 DOI: 10.3390/ijerph17072404] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 03/17/2020] [Accepted: 03/30/2020] [Indexed: 02/07/2023]
Abstract
Contact allergy (sensitisation) and allergic contact dermatitis (ACD) resulting from it have a considerable public health impact. For the present review, all pertinent articles were systematically searched via Medline and Web of Science™; additionally, all available issues of the journals "Contact Dermatitis" and "Dermatitis" were manually searched, covering the years 2018-2019, thereby extending and re-focusing a previous similar review. New allergens, or previously described allergens found in a new exposure context or of other current importance, are described in sections according to substance classes, e.g., metals, preservatives, fragrances. As a common finding in many investigations, a lack of information on product composition has been noted, for instance, regarding a newly described allergen in canvas shoes (dimethylthiocarbamylbenzothiazole sulfide) and, most notably, absence of co-operation from manufacturers of glucose-monitoring devices and insulin pumps, respectively. These latter devices have been shown to cause severe ACD in a considerable number of diabetic patients caused by the liberation of isobornyl acrylate and N,N'-dimethylacrylamide, respectively, as demonstrated by an international collaboration between dermatologists and chemists. Improved and complete ingredient labelling for all types of products, and not just cosmetics, must be put on the legislative agenda.
Collapse
|
9
|
|
10
|
Topical Drugs. Contact Dermatitis 2020. [DOI: 10.1007/978-3-319-72451-5_38-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
11
|
Goossens A, Gonçalo M. Contact Allergy to Topical Drugs. Contact Dermatitis 2020. [DOI: 10.1007/978-3-319-72451-5_38-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
12
|
Herman A, Goossens A. The need to disclose the composition of medical devices at the European level. Contact Dermatitis 2019; 81:159-160. [DOI: 10.1111/cod.13354] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Anne Herman
- Department of DermatologyCliniques universitaires Saint‐Luc, Brussels, Belgium
- Institute of Experimental and Clinical ResearchPneumology, ENT and Dermatology Pole, Université catholique de Louvain Brussels Belgium
| | - An Goossens
- Department of DermatologyUniversity Hospitals, KU Leuven Leuven Belgium
| |
Collapse
|
13
|
Herman A, Mowitz M, Aerts O, Pyl J, Montjoye L, Goossens A, Bruze M, Baeck M. Unexpected positive patch test reactions to sesquiterpene lactones in patients sensitized to the glucose sensor FreeStyle Libre. Contact Dermatitis 2019; 81:354-367. [DOI: 10.1111/cod.13330] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Revised: 05/28/2019] [Accepted: 06/03/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Anne Herman
- Department of Dermatology, Cliniques universitaires Saint‐Luc, Brussels, and IREC (Institut de Recherche Experimentale et Clinique) Pôle Pneumologie, ORL, DermatologieUniversité Catholique de Louvain Brussels Belgium
| | - Martin Mowitz
- Department of Occupational and Environmental Dermatology, Lund UniversitySkåne University Hospital Malmö Sweden
| | - Olivier Aerts
- Department of DermatologyUniversity Hospital Antwerp (UZA) and University of Antwerp (UA) Antwerp Belgium
| | - Jeroen Pyl
- Department of DermatologyUniversity Hospital Antwerp (UZA) and University of Antwerp (UA) Antwerp Belgium
| | - Laurence Montjoye
- Department of Dermatology, Cliniques universitaires Saint‐Luc, Brussels, and IREC (Institut de Recherche Experimentale et Clinique) Pôle Pneumologie, ORL, DermatologieUniversité Catholique de Louvain Brussels Belgium
| | - An Goossens
- Department of DermatologyUniversity Hospitals Leuven Belgium
| | - Magnus Bruze
- Department of Occupational and Environmental Dermatology, Lund UniversitySkåne University Hospital Malmö Sweden
| | - Marie Baeck
- Department of Dermatology, Cliniques universitaires Saint‐Luc, Brussels, and IREC (Institut de Recherche Experimentale et Clinique) Pôle Pneumologie, ORL, DermatologieUniversité Catholique de Louvain Brussels Belgium
| |
Collapse
|
14
|
Bhoyrul B, Solman L, Kirk S, Orton D, Wilkinson M. Patch testing with alkyl glucosides: Concomitant reactions are common but not ubiquitous. Contact Dermatitis 2018; 80:286-290. [DOI: 10.1111/cod.13186] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Revised: 11/15/2018] [Accepted: 11/17/2018] [Indexed: 11/29/2022]
Affiliation(s)
- Bevin Bhoyrul
- Department of Dermatology; Chapel Allerton Hospital; Leeds UK
| | - Lea Solman
- Department of Dermatology; Chapel Allerton Hospital; Leeds UK
- Department of Dermatology; Great Ormond Street Hospital for Children; London UK
| | | | | | - Mark Wilkinson
- Department of Dermatology; Chapel Allerton Hospital; Leeds UK
| |
Collapse
|